Analysts Set Expectations for CRVS FY2025 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($0.46) per share for the year. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share.

A number of other equities analysts have also recently weighed in on the company. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. Finally, Oppenheimer upped their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Corvus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ CRVS opened at $5.22 on Wednesday. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00. The company has a market capitalization of $335.44 million, a price-to-earnings ratio of -5.61 and a beta of 1.07. The business has a 50-day moving average of $6.86 and a 200-day moving average of $5.61.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CRVS. Cubist Systematic Strategies LLC acquired a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter valued at about $44,000. Nwam LLC acquired a new stake in Corvus Pharmaceuticals during the third quarter valued at approximately $53,000. XTX Topco Ltd bought a new position in Corvus Pharmaceuticals during the 3rd quarter worth approximately $74,000. Virtu Financial LLC acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth approximately $83,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at approximately $89,000. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.